Short answer
Adaptive Biotechnologies Corp (ADPT) filed an 8-K current report with the SEC on June 15, 2026 reporting Item 8.01 (Other Events), Item EX-99.1 (Exhibit EX-99.1). Planned $250 million convertible senior notes due 2031, subject to market conditions and qualified institutional buyers.
Adaptive Biotechnologies Corp 8-K event analysis
AI summary of each reported item and its exhibits
Item 8.01 · Other Events
- Planned $250 million convertible senior notes due 2031, subject to market conditions and qualified institutional buyers
- Initial purchasers may buy up to an additional $37.5 million under a 13-day option
- Proceeds coincide with planned separation of MRD and Immune Medicine businesses
- Business separation introduces potential strategic and execution risk for shareholders
Item EX-99.1 · Exhibit EX-99.1
- Proposed $250 million convertible senior notes due July 1, 2031, plus potential $37.5 million overallotment
- Proceeds targeted for OrbiMed Purchase Agreement repayment, improving financial flexibility
- Up to $25 million share repurchase could reduce dilution but may support the stock price and raise conversion pricing
- Capped calls intended to offset conversion dilution, though protection ends above the capped-call price
- Interest rate and conversion terms remain undetermined until pricing, creating execution and dilution uncertainty
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Adaptive Biotechnologies Corp 8-K filings
Get the next ADPT 8-K as it lands
Follow ADPT for push alerts, or ask the research agent what this filing means.